Core Viewpoint - The company, Yidu Tech (02158), has demonstrated healthy growth in its business, achieving a total revenue of RMB 358 million, representing a year-on-year increase of 8.7% [1][1][1] Financial Performance - The adjusted EBITDA for existing business reached approximately RMB 54 million, doubling compared to the same period last year [1][1][1] - The company has nearly achieved breakeven at the accounting level, reaching this key financial milestone about a year earlier than management's previous expectations [1][1][1] Market Activity - On December 3, the company repurchased 392,000 shares at a price of HKD 5.09 per share, with a total repurchase amount of approximately HKD 2 million [1][1][1] Analyst Sentiment - Brokerages are releasing positive signals regarding the company, with Everbright Securities highlighting Yidu Tech's continuous breakthroughs in the AI medical innovation field [1][1][1] - Citigroup has maintained a "Buy" rating for the company, setting a target price of HKD 10, recognizing its core competitiveness and growth potential in the AI healthcare sector [1][1][1]
医渡科技斥资200万港元回购 2026财年中期业绩亮眼